AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04058366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination (FDC) tablet for oral administration.
Study NCT04058366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study NCT01589237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Study NCT01672723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Study NCT01672723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone
Study NCT02314910 — intervention group
Intervention type: OTHER
Intervention: Sample histology
Study NCT03081052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iNO
Description: Subject will receive inhaled Nitric Oxide in this intervention
Study NCT03081052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iEPO
Description: Subject will receive inhaled Epoprostrenol in this intervention
Study NCT04150601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIMEOX
Description: SIMEOX is a device generating a succession of gentle depression at the mouth.
Study NCT04150601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEP
Description: A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
Study NCT04150601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous Exhalation
Description: A slow vital capacity maneuver will be performed according to the guidelines, from total lung capacity to residual volume
Study NCT00558194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Behavioral Weight Loss Treatment with Affective and Cognitive Skills Training
Description: 12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
Study NCT00558194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss Treatment
Description: 12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
Study NCT00006373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Etoposide IV 500 mg/m2/day over 24 hours Days -5, -4, -3
Study NCT00006373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Ifosfamide 3,333 mg/m2/day IV over 2 hours (total dose 10,000 mg/m2)Days -8, -7, -6
Study NCT01374438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSDC-0160
Description: MSDC-0160 150 mg capsules given once daily for 90 days
Study NCT01374438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules given once daily for 90 days
Study NCT02734875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention arm offers primary care providers additional information on patient risks and benefits as well as an offer of assistance with managing a patient's anticoagulation from a respected service at BWH.
Study NCT03227913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two samples of saliva
Description: 1. Without stimulation: the first will be used to measure the flow of naturally secreted saliva~2. With stimulation: the second will will be used to measure the flow and viscosity of the saliva secreted after stimulation
Study NCT03227913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two samples of saliva
Description: 1. Without stimulation: the first will be used to measure the flow of naturally secreted saliva~2. With stimulation: the second will will be used to measure the flow and viscosity of the saliva secreted after stimulation
Study NCT03227913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chewing behaviour
Description: Measure the time taken by subjects to chew the food and the number of bites they use before swallowing
Study NCT03227913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing behaviour
Description: Measure the time taken by subjects to chew the food and the number of bites they use before swallowing
Study NCT03227913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study of the food bolus
Description: * Analysis by a compression and viscosity test~* Evaluation of the quantity of saliva incorporated by drying
Study NCT03227913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study of the food bolus
Description: * Analysis by a compression and viscosity test~* Evaluation of the quantity of saliva incorporated by drying
Study NCT03667378 — intervention group
Intervention type: BEHAVIORAL
Intervention: Expectations Survey (CanCORS)
Description: Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
Study NCT03667378 — intervention group
Intervention type: BEHAVIORAL
Intervention: Values Survey (Serious Illness Care Program)
Description: Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
Study NCT03667378 — intervention group
Intervention type: BEHAVIORAL
Intervention: Functional Assessment of Cancer Therapy-General (FACT-G)
Description: Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
Study NCT03667378 — intervention group
Intervention type: BEHAVIORAL
Intervention: NCCN Distress Thermometer
Description: Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
Study NCT03667378 — intervention group
Intervention type: BEHAVIORAL
Intervention: Hospital Anxiety and Depression Scale (HADS)
Description: Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
Study NCT00006373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Topotecan 21.3 mg/m2/day (total dose 64 mg/m2 ) IV over 30 minutes Days -8, -7, -6
Study NCT00006373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Study NCT03667378 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Communication (QOC)
Description: Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
Study NCT00006373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna 1,111 mg/m2/dose IV over 30 minutes; 30 minutes before and 4 and 8 hours after ifosfamide (total dose 10,000 mg/m2) Days -8, -7, -6
Study NCT03667378 — intervention group
Intervention type: BEHAVIORAL
Intervention: visits with a supportive care clinician
Description: Monthly visits with a supportive care clinician
Study NCT02708836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction of anesthesia
Description: At the discretion of the primary anesthesiologist. Typically involves the administration of an analgesic agent, hypnotic agent, and neuromuscular blocking agent
Study NCT02708836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induction of anesthesia
Description: At the discretion of the primary anesthesiologist. Typically involves the administration of an analgesic agent, hypnotic agent, and neuromuscular blocking agent
Study NCT02708836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of LMA [Ambu (R) AuraGain (TM) disposable laryngeal mask]
Description: By standard method. Sizing at the discretion of the primary anesthesiologist.
Study NCT04734093 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of sonographic signs of gouty arthritis
Description: the EULAR scanning protocol for the knee and 1st MTP will be considered \[2\]. Further, scanning of the double contour sign over the femur condyles anteriorly and posteriorly in sagittal planes will be assessed. Examination of erosions, tophus, double contour, effusion, and echogenic foci will be recorded.
Study NCT02708836 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy and placement of ETT
Description: Via direct or indirect laryngoscopy. Sizing at the discretion of the primary anesthesiologist. Mallinckrodt (TM) Intermediate Hi-Lo cuffed endotracheal tube (Covidien)
Study NCT02708836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation via the ETT
Description: Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
Study NCT02708836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation via the ETT
Description: Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
Study NCT02708836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of the ETT
Description: Either upon emergence of anesthesia after suctioning of the oropharynx and after a positive pressure breath or while deeply anesthetized after release of the pneumoperitoneum in the combined LMA/ETT group.
Study NCT02708836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removal of the ETT
Description: Either upon emergence of anesthesia after suctioning of the oropharynx and after a positive pressure breath or while deeply anesthetized after release of the pneumoperitoneum in the combined LMA/ETT group.
Study NCT02708836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation of the trachea through the LMA
Description: With ETT using fiberoptic bronchoscope guidance.
Study NCT02708836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation via the LMA
Description: After removal of the ETT. Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
Study NCT02708836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergence from anesthesia
Description: At the discretion of primary team. Airway device (either ETT or LMA) will be removed when patient is adequately ventilating and able to respond to commands (such as open your eyes or squeeze my hand).
Study NCT02708836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergence from anesthesia
Description: At the discretion of primary team. Airway device (either ETT or LMA) will be removed when patient is adequately ventilating and able to respond to commands (such as open your eyes or squeeze my hand).
Study NCT02855125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-114
Description: TAS-114 was a modulator of 5-fluorouracil (5-FU).
Study NCT02855125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1 was designed to provide oral delivery of 5-FU and to reduce the rate of degradation of 5-FU in vivo.
Study NCT00183365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Skills Training
Description: Parent skills training will include 10 weeks of psychoeducational and skills training group sessions for parents.
Study NCT00183365 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Skills Training
Description: Parent skills training will include 10 weeks of psychoeducational and skills training group sessions for parents.
Study NCT00183365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protecting Families Program (PFP)
Description: Participants will receive 10 weeks of PFP, which will include a community meal at the beginning of each session, a parent skills training group, and a concurrent cognitive behavioral therapy (CBT) group for the focal child.
Study NCT01135407 — intervention group
Intervention type: OTHER
Intervention: Recording during computerized tests
Description: Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.~The computerized tests are administered in two different conditions of medication: with or without dopaminergic treatment, corresponding to two different experimental sessions.
Study NCT01135407 — intervention group
Intervention type: OTHER
Intervention: Recording during computerized tests
Description: Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals. The computerized tests are administered in three different sets of electrical (without stimulation, or selective stimulation of the sensorimotor or associative/limbic part of the subthalamic nucleus) stimulation, corresponding to three different experimental sessions.
Study NCT01135407 — intervention group
Intervention type: OTHER
Intervention: Recording during computerized tests
Description: Participants will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.The computerized tests are administered twice (in two different experimental sessions) to verify the performance repeatability.
Study NCT02915302 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone Quadrivalent vaccine, No Preservative
Description: 0.25-mL (Pediatric Dose), Intramuscular (2016-2017 formulation)
Study NCT02915302 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, No Preservative
Description: 0.5-mL, Intramuscular (2016-2017 formulation)
Study NCT04288765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Only Product in Parenteral Dose Form
Description: Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21~Daratumumab:~Cycles 1-2: weekly Cycles 3-4: every two weeks Cycles 5-8: every month Dexamethasone: 40 mg weekly
Study NCT04288765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab Only Product in Parenteral Dose Form
Description: Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21~Daratumumab:~Cycles 1-2: weekly Cycles 3-4: every two weeks Cycles 5-8: every month Dexamethasone: 40 mg weekly
Study NCT03059069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chonline Alphoscerate
Description: Patients treated with Chonline Alphoscerate as add on therapy to their medication
Study NCT03059069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Patients maintain their medication with either Gliatamin or placebo for 6 months.
Study NCT01189084 — intervention group
Intervention type: BIOLOGICAL
Intervention: Observational
Description: Measure anti-Amyloid-beta antibody in serum during 24-26 weeks extension period to 48 weeks (after first vaccine treatment).
Study NCT00095732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase
Description: Administered orally as either Size 2 capsules (20,000 Units lipase; 20,000 Units protease; and 3,000 Units amylase) or Size 5 capsules (5,000 Units lipase; 5,000 Units protease; and 750 Units amylase)
Study NCT00095732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally in either Size 2 or Size 5 capsules
Study NCT00160784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopy
Description: Randomized placement into 2 groups; arthroscopic manipulation or home therapy
Study NCT00160784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic manipulation
Description: Manipulation of shoulder performed during arthroscopy
Study NCT00160784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home therapy
Description: Shoulder exercise program performed at home that may increase shoulder function
Study NCT02860780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prexasertib
Description: Administered IV
Study NCT02860780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ralimetinib
Description: Administered orally
Study NCT03129880 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weekly Voice Therapy
Description: Participants will be randomized to receive weekly voice therapy
Study NCT03129880 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Voice Therapy
Description: Participants will be randomized to receive multiple sessions of voice therapy in one day.
Study NCT00444899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Description: Subjects will be followed by the dietician in combination with his/her endocrinologist. Diet, physical activity, smoking cessation and drug prescriptions will be used to treat subjects.
Study NCT00444899 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal follow-up
Description: Subject will continue to be followed by their endocrinologist and general practitioner as they already do.
Study NCT01886612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duo-STIM neuromuscular electrical stimulator
Study NCT01886612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AV Impulse System Model 6000
Study NCT02198079 — intervention group
Intervention type: BIOLOGICAL
Intervention: Sputum
Study NCT03809429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049 + GnRH agonist (GONAPEPTYL)
Description: Pre-filled injection pen
Study NCT03809429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FE 999049 + GnRH antagonist (CETROTIDE)
Description: Powder and solvent for solution for injection
Study NCT02480153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06410293
Description: PF-06410293 will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
Study NCT02480153 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
Study NCT02831803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: 28 gm/day in single-serve package
Study NCT02831803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil
Description: 32 gm/day provided in 3, 34 ounce bottles
Study NCT00737971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab intravitreal
Description: Bevacizumab intravitreal 0.05 ml/1.25 mg - administered on D0, Week 4, Week 8
Study NCT00737971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Intravitreal 0.1 ml/4 mg, D0, Week 4 and Week 8
Study NCT00737971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone + Bevacizumab
Description: Intravitreal triamcinolone 0.1 ml/4 mg + bevacizumab 0.05 ml/1.25 mg simultaneously on D0, week 4, Week 8
Study NCT00512317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganaxolone
Description: liquid suspension dosed tid
Study NCT03775070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: * Starting dosage: in adult, the dose of simvastatin is 10 mg once daily. In children, the dose is 0.25mg/Kg/day (maximum dose: 10 mg/d).~* Target dosage: in adult, the dose of simvastatin is 20 mg once daily. In children, the dose is 0.5mg/Kg/day (maximum dose: 20 mg/d).~* The basic anti-congestive medication will be kept as the same.~* The dosage may be titrated to a lesser dose by investigators according to the patient's condition.
Study NCT02258308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW intervention
Description: Home education and support for asthma self management